Long-term follow-up of patients with hepatitis C with a normal alanine aminotransferase

Journal of Medical Virology

Volumn 81, Issue 3, 2009, Pages 446-451

  Kumada, Takashi ^a,b   Toyoda, Hidenori ^a   Kiriyama, Seiki ^a   Sone, Yasuhiro ^a   Tanikawa, Makoto ^a   Hisanaga, Yasuhiro ^a   Kanamori, Akira ^a   Atsumi, Hiroyuki ^a   Takagi, Makiko ^a   Nakano, Satoshi ^a   Arakawa, Takahiro ^a   Fujimori, Masashi ^a  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b NONE   (Japan)

Author keywords

Chronic hepatitis C; Hepatitis C virus; Hepatocarcinogenesis; Long term follow up; Normal alanine aminotransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; SEX DIFFERENCE; BLOOD; CHILD; LIVER; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

HEPATITIS C VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; CARCINOMA, HEPATOCELLULAR; CHILD; CHOLESTEROL; FEMALE; HEPATITIS C; HUMANS; L-LACTATE DEHYDROGENASE; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS;

EID: 60049097897     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21342     Document Type: Article

References (27)

1. Alberti A. 2005. Towards more individualized management of hepatitis C virus patients with initially or persistently normal alanine aminotransferase levels. J Hepatol 42:266-274.
2. Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, Ruol A. 1992. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 340:697-698.
3. Alberti A, Chemello L, Benvegnu L. 1999. Natural history of hepatitis C. J Hepatol 31:S17-S24.
4. Alberti A, Benvegnu L, Boccato S, Ferrari A, Sebastiani G. 2004. Natural history of initially mild chronic hepatitis C. Dig Liver Dis 36:646-654.
5. Bacon BR. 2002. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36:S179-S184.
6. Craxi A, Almasio P. 1996. Diagnostic approach to liver enzyme elevation. J Hepatol 25:S47-S51.
7. EASL International Consensus Conference on Hepatitis C. 1999. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 30:956-961.
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
9. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group. 2004. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355.
10. Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S. 2000. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 181:1523-1527.
11. Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Kondo J, Yamauchi T, Nakano S. 2007. Relation between incidence of hepatic carcinogenesis and integration value of alanine aminotransferase in patients with hepatitis C virus infection. Gut 56:738-739.
12. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 358:958-965.
13. Marcellin P. 1999. Hepatitis C: The clinical spectrum of the disease. J Hepatol 31:S9-S16.
14. Marcellin P, Levy S, Erlinger S. 1997. Therapy of hepatitis C: Patients with normal aminotransferase levels. Hepatology 26:S133-S136.
15. Ohmiya M, Hayashi J, Ueno K, Furusyo N, Sawayama Y, Kawakami Y, Kinukawa N, Kashiwagi S. 2000. Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels. Dig Dis Sci 45:1953-1958.
16. Okanoue T, Makiyama A, Nakayama M, Sumida Y, Mitsuyoshi H, Nakajima T, Yasui K, Minami M, Itoh Y. 2005. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 43:599-605.
17. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, Sansonetti N, Opolon P. 1998. Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 27:1213-1219.
18. Prati D, Capelli C, Zanella A, Mozzi F, Bosoni P, Pappalettera M, Zanuso F, Vianello L, Locatelli E, de Fazio C, Ronchi G, del Ninno E, Colombo M, Sirchia G. 1996. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology 110:178-183.
19. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G. 2002. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1-10.
20. Pratt DS, Kaplan MM. 2000. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342:1266-1271.
21. Puoti C. 2003. HCV carriers with persistently normal aminotransferase levels: Normal does not always mean healthy. J Hepatol 38:529-532.
22. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, Aldegheri L, Resta S. 1997. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 26:1393-1398.
23. Puoti C, Castellacci R, Montagnese F, Zaltron S, Stornaiuolo G, Bergami N, Bellis L, Precone DF, Corvisieri P, Puoti M, Minola E, Gaeta GB. 2002. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: The Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 37:117-123.
24. Tassopoulos NC. 1999. Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol 31:S193-S196.
25. Tsuji K, Yamasaki K, Yamanishi M, Kawakami M, Shirahama S. 2001. Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: A 10-year follow-up study. J Gastroenterol Hepatol 16:536-540.
26. Zanella A, Conte D, Prati D, Mozzi F, Capelli C, Zanuso F, Fraquelli M, Bosoni P, Vianello L, Pappalettera M, Velio P, Montagnolo G, Bianchi PA, Sirchia G. 1995. Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second-generation recombinant immunoblot assay. Hepatology 21:913-917.
27. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB, Lamour F, Lardelli P. PEGASYS Study NR16071 Investigator Group. 2004. Peginterferon alfa-2a (40 kiloDaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127:1724-1732.